5-bromo-3-ethylpyridin-2-amine | 1037253-14-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-bromo-3-ethylpyridin-2-amine
• CAS: 1037253-14-7
• 化学式: C₇H₉BrN₂
• 分子量: 201.066
• InChiKey: JYVIQBPXESSJDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-bromo-3-ethylpyridin-2-amine 在 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 亚硝酸丁酯 、 copper(l) chloride 、 copper dichloride 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 6-chloro-5-ethylnicotinonitrile
  参考文献：
  名称：

  WO2019177997A5

  摘要：

  公开号：

  WO2019177997A5
• 作为产物：
  描述：

  2-氨基-3-甲基吡啶 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 正丁基锂 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 、 水 、 乙酸乙酯 为溶剂， 反应 6.0h， 生成 5-bromo-3-ethylpyridin-2-amine
  参考文献：
  名称：

  PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT

  摘要：

  本发明涵盖了Formula I的化合物。 其中： R1、R2、R3、R4、R5、Ra、Rb、Q1和Q2在规范中有定义。 该发明还涵盖了一种治疗或改善ROR-γ-t介导的综合征、疾病或疾病的方法，包括综合征、疾病或疾病选自类风湿性关节炎、银屑病性关节炎和牛皮癣的方法。该发明还涵盖了通过给哺乳动物施用至少一种Formula I化合物的治疗有效量来调节RORγt活性的方法。

  公开号：

  US20190382354A1

文献信息

• Novel Heterocyclic Compounds and Uses Thereof
  申请人：Huang Zilin

  公开号：US20130210818A1

  公开（公告）日：2013-08-15

  New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代杂环化合物，含有它们的组合物，以及使用它们抑制Raf激酶活性的方法。这些新化合物和组合物可以单独使用，也可以与至少一种额外的药物联合使用，用于治疗由Raf激酶介导的疾病，如癌症。
• IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS
  申请人：BIOGEN MA INC.

  公开号：US20220089592A1

  公开（公告）日：2022-03-24

  This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

  这项发明涉及Imidazo[1,2-a]pyridinyl Derivatives的化合物（I′）或其药学上可接受的盐，其中所有变量如规范中所定义，能够调节IRAK4的活性。该发明进一步提供了一种制造该发明化合物的方法，以及它们在治疗中的方法。该发明还提供了它们的制备方法，医学用途，特别是在治疗和管理炎症性疾病、自身免疫疾病、癌症、心血管疾病、中枢神经系统疾病、皮肤疾病、眼科疾病和骨骼疾病等疾病或疾病的用途。
• Novel heterocyclic compounds and uses therof
  申请人：Hunag Zilin

  公开号：US20100003246A1

  公开（公告）日：2010-01-07

  New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  本文提供了新的取代杂环化合物、含有它们的组合物以及使用它们抑制Raf激酶活性的方法。这些新化合物和组合物可以单独或与至少一种其他药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• Novel aminopyrimidine derivatives as PLK1 inhibitors
  申请人：Hashihayata Takashi

  公开号：US20080305081A1

  公开（公告）日：2008-12-11

  The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R 1 and R 2 , which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R 3 and R 4 , which may be the same or different, are each a hydrogen atom, a lower alkyl group, NR a R b , a phenyl group, a lower alkyl group substituted with a phenyl group, a 4- to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5- or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5- or 6-membered aromatic heterocyclic group, or the like; and R 5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

  本发明涉及由公式[I]表示的化合物，或其药学上可接受的盐或酯，其中R1和R2（可以相同也可以不同）分别是氢原子、低碳基、环烷基或类似物；R3和R4（可以相同也可以不同）分别是氢原子、低碳基、NRaRb、苯基、带苯基的低碳基、4-至7-成员的脂环杂环基、带4-至7-成员的脂环杂环基的低碳基、5-或6-成员的芳香杂环基、带5-或6-成员的芳香杂环基的低碳基或类似物；R5是氢原子、氰基、卤素原子或低碳基。
• Aminopyrimidine derivatives as PLK1 inhibitors
  申请人：Banyu Pharmaceutical Co. Ltd

  公开号：US07977336B2

  公开（公告）日：2011-07-12

  The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R3 and R4, which may be the same or different, are each a hydrogen atom, a lower alkyl group, NRaRb, a phenyl group, a lower alkyl group substituted with a phenyl group, a 4-to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5-or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5-or 6-membered aromatic heterocyclic group, or the like; and R5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

  本发明涉及一种由式[I]表示的化合物，或其药学上可接受的盐或酯，其中R1和R2，可以相同也可以不同，分别是氢原子，低碳基，环烷基或类似物；R3和R4，可以相同也可以不同，分别是氢原子，低碳基，NRaRb，苯基，带有苯基的低碳基，4-至7-成员脂环杂环基，带有4-至7-成员脂环杂环基的低碳基，5-或6-成员芳香杂环基，带有5-或6-成员芳香杂环基的低碳基或类似物；而R5是氢原子，氰基，卤素原子或低碳基。